{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:48:08Z","timestamp":1753876088075,"version":"3.41.2"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-16-CONV000X","ANR-17-EURE-0029"],"award-info":[{"award-number":["ANR-16-CONV000X","ANR-17-EURE-0029"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Excellence Initiative of Aix Marseille University","award":["AMX-19-IET-004"],"award-info":[{"award-number":["AMX-19-IET-004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite its wide use to treat various inflammatory diseases, infliximab becomes ineffective in some patients due to inadequate drug levels and production of anti-drug antibodies (ADA). The aim of this study was to compare the prevalence and ADA levels in a large cohort of patients. ADA and infliximab (IFX) through levels measured by enzyme-linked immunosorbent assay were collected from 505 patients within a period of 4 years. The results indicate that (i) 13.5% of patients produce ADA, (ii) male patients were more likely to produce ADA at levels above 10 000\u00a0ng\/ml than female patients, (iii) ADA levels were lower when associated with immunosuppressant drugs, (iv) there was an inverse relationship between ADA presence and IFX detection, and (v) no correlation was observed between ADA levels and number of injections or brand of IFX administered. This study improves our understanding of the factors promoting IFX immunogenicity and highlights the need to develop personalized treatment strategies.<\/jats:p>","DOI":"10.1093\/cei\/uxae122","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T15:28:03Z","timestamp":1734967683000},"source":"Crossref","is-referenced-by-count":0,"title":["Detection of antibodies to infliximab in routine care: a 4-year French retrospective study"],"prefix":"10.1093","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7172-8865","authenticated-orcid":false,"given":"Daniel","family":"Bertin","sequence":"first","affiliation":[{"name":"Immunology Laboratory, Biogenop\u00f4le, H\u00f4pital de la Timone , APHM , Marseille,","place":["France"]},{"name":"CNRS, INP, Institute of Neurophysiopathology, Aix-Marseille University , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehanne","family":"Aghzadi","sequence":"additional","affiliation":[{"name":"CNRS, INP, Institute of Neurophysiopathology, Aix-Marseille University , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Balandraud","sequence":"additional","affiliation":[{"name":"Rheumatology Department, H\u00f4pital Sainte Marguerite , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Roman","sequence":"additional","affiliation":[{"name":"Multidisciplinary Pediatrics Department , H\u00f4pital de la Timone, APHM , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Me\u0301lanie","family":"Serrero","sequence":"additional","affiliation":[{"name":"Gastroenterology Department , Ho\u0302pital Nord, APHM , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Desplat-J\u00e9go","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Biogenop\u00f4le, H\u00f4pital de la Timone , APHM , Marseille,","place":["France"]},{"name":"CNRS, INP, Institute of Neurophysiopathology, Aix-Marseille University , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"2025041017400617100_CIT0001","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-l","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"2025041017400617100_CIT0002","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to Anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025041017400617100_CIT0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5639\/gabij.2019.0801.003","article-title":"Patent expiry dates for biologicals: 2018 update","volume":"8","author":"GaBI Journal Editor","year":"2019","journal-title":"GABI J"},{"key":"2025041017400617100_CIT0004","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"2025041017400617100_CIT0005","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14787210.2023.2151438","article-title":"Infliximab as a potential treatment for COVID-19","volume":"21","author":"Velez","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025041017400617100_CIT0006","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025041017400617100_CIT0007","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3899\/jrheum.140538","article-title":"Incidence and management of infusion reactions to infliximab in a prospective real-world community registry","volume":"42","author":"Choquette","year":"2015","journal-title":"J Rheumatol"},{"key":"2025041017400617100_CIT0008","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10067-015-2929-7","article-title":"Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL","volume":"34","author":"Faf\u00e1","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025041017400617100_CIT0009","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025041017400617100_CIT0010","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/joim.13495","article-title":"Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial","volume":"292","author":"Brun","year":"2022","journal-title":"J Intern Med"},{"key":"2025041017400617100_CIT0011","first-page":"163","article-title":"Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem","volume":"70","author":"Baert","year":"2007","journal-title":"Acta Gastroenterol Belg"},{"key":"2025041017400617100_CIT0012","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-Inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol"},{"key":"2025041017400617100_CIT0013","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2025041017400617100_CIT0014","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","article-title":"Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics","volume":"55","author":"Gill","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2025041017400617100_CIT0015","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"2025041017400617100_CIT0016","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.semarthrit.2018.10.006","article-title":"Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis","volume":"48","author":"Quistrebert","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025041017400617100_CIT0017","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/ard.2009.112847","article-title":"Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study","volume":"69","author":"Bartelds","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025041017400617100_CIT0018","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"2025041017400617100_CIT0019","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"key":"2025041017400617100_CIT0020","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40259-021-00507-5","article-title":"Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis","volume":"35","author":"Bots","year":"2021","journal-title":"BioDrugs"},{"key":"2025041017400617100_CIT0021","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"2025041017400617100_CIT0022","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/MIB.0000000000000284","article-title":"Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD","volume":"21","author":"Zitomersky","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2025041017400617100_CIT0023","doi-asserted-by":"publisher","first-page":"801532","DOI":"10.3389\/fmed.2021.801532","article-title":"Relationship between patient sex and serum tumor necrosis factor antagonist drug and anti-drug antibody concentrations in inflammatory bowel disease: a Nationwide Cohort Study","volume":"8","author":"Shehab","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025041017400617100_CIT0024","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/03009742.2019.1602670","article-title":"Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population","volume":"48","author":"Hambardzumyan","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2025041017400617100_CIT0025","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5863\/1551-6776-27.1.63","article-title":"Comparison of timing to develop anti-drug antibodies to infliximab and adalimumab between adult and pediatric age groups, males and females","volume":"27","author":"Trotta","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2025041017400617100_CIT0026","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2025041017400617100_CIT0027","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/08820139009041841","article-title":"The effect of testosterone on the immune response. 1. Mechanism of action on antibody-forming cells","volume":"19","author":"Rif\u00e9","year":"1990","journal-title":"Immunol Invest"},{"key":"2025041017400617100_CIT0028","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.tranon.2020.100759","article-title":"Immune suppression in pregnancy and cancer: parallels and insights","volume":"13","author":"Kareva","year":"2020","journal-title":"Transl Oncol"},{"key":"2025041017400617100_CIT0029","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.msard.2019.06.021","article-title":"A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer acetate in relapsing-remitting multiple sclerosis patients","volume":"34","author":"Avila","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"2025041017400617100_CIT0030","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/all.13471","article-title":"IgG4 anti-infliximab in treated patients: clinical impact and temporal evolution","volume":"73","author":"Vultaggio","year":"2018","journal-title":"Allergy"},{"key":"2025041017400617100_CIT0031","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fphar.2019.00047","article-title":"Sex differences in response to TNF-inhibiting drugs in patients with spondyloarthropathies or inflammatory bowel diseases","volume":"10","author":"Lagan\u00e0","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025041017400617100_CIT0032","doi-asserted-by":"crossref","first-page":"1759720X","DOI":"10.1177\/1759720X211002685","article-title":"Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults","volume":"13","author":"Parikh","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025041017400617100_CIT0033","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/apt.15312","article-title":"Letter: immunogenicity of anti-TNF in elderly IBD patients","volume":"50","author":"Paul","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025041017400617100_CIT0034","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"2025041017400617100_CIT0035","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025041017400617100_CIT0036","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.dld.2019.02.013","article-title":"Infliximab therapy intensification upon loss of response: is there an optimal trough level","volume":"51","author":"Ungar","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2025041017400617100_CIT0037","doi-asserted-by":"publisher","first-page":"154859","DOI":"10.1016\/j.cyto.2019.154859","article-title":"Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: a comparison of three commercially available ELISA kits","volume":"126","author":"Bertin","year":"2020","journal-title":"Cytokine"},{"issue":"5844","key":"2025041017400617100_CIT0038","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"2025041017400617100_CIT0039","doi-asserted-by":"publisher","first-page":"14976","DOI":"10.1038\/s41598-021-94431-x","article-title":"Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients\u2019 sera","volume":"11","author":"Beeg","year":"2021","journal-title":"Sci Rep"},{"key":"2025041017400617100_CIT0040","doi-asserted-by":"publisher","first-page":"17562848231170948","DOI":"10.1177\/17562848231170948","article-title":"Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn\u2019s disease patients with secondary loss of response","volume":"16","author":"Kim","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"2025041017400617100_CIT0041","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"key":"2025041017400617100_CIT0042","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient","volume":"108","author":"Vande Casteele","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2025041017400617100_CIT0043","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjv061","article-title":"Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease","volume":"9","author":"Roblin","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2025041017400617100_CIT0044","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/MCG.0000000000001469","article-title":"Intermittent appearance of antibodies to infliximab is not associated with reduced efficacy in patients with inflammatory bowel diseases","volume":"56","author":"Awadie","year":"2022","journal-title":"J Clin Gastroenterol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae122\/61266629\/uxae122.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxae122\/61266629\/uxae122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxae122\/61266629\/uxae122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T17:40:17Z","timestamp":1744306817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxae122\/7931526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae122","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"type":"print","value":"0009-9104"},{"type":"electronic","value":"1365-2249"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,23]]},"article-number":"uxae122"}}